RESUMEN
We describe 3 fatal cases of interstitial pneumonitis rapidly evolving to pulmonary fibrosis and death after the administration of oxaliplatin as part of the FOLFOX regimen. Due to the widespread use of oxaliplatin in oncology, clinicians should be aware of the risk and severity of oxalipatin-induced interstitial pneumonia.
RESUMEN
A case of synchronous concurrent carcinoma and primary malignant lymphoma developing as two independent tumors of the stomach is presented. The clinical and pathological diagnosis and therapeutic problems associated with synchronous tumors of the stomach are discussed. A possible relationship between the two tumors and the role of Helicobacter pylori are also reviewed.
Asunto(s)
Carcinoma/patología , Linfoma/patología , Neoplasias Primarias Múltiples/patología , Neoplasias Gástricas/patología , Anciano , Carcinoma/cirugía , Femenino , Humanos , Linfoma/cirugía , Neoplasias Primarias Múltiples/cirugía , Neoplasias Gástricas/cirugíaRESUMEN
Strongyloides stercoralis hyperinfection syndrome is a rare complication of strongyloidiasis that occurs in immunosuppressed patients. It is caused by increasing autoinfection of the host by the nematode, leading to serious superimposed enterobacterial sepsis. Once established, it has a high fatality rate. Two cases are reported of Strongyloides hyperinfection in patients with lymphoma who presented with purulent meningitis. Both were receiving combination chemotherapy that included high-dose corticosteroids, and neither was granulocytopenic at infectious onset. The patients had respiratory insufficiency that required mechanical ventilation and serious septic episodes. Both were treated with thiabendazole, and one survived with clearance of the larvae. These cases illustrate the possibility of strongyloidiasis hyperinfection as an underlying diagnosis of purulent meningitis and serious septic episodes in lymphomatous patients. It may occur even without granulocytopenia.
Asunto(s)
Linfoma de Células B Grandes Difuso/complicaciones , Linfoma no Hodgkin/complicaciones , Meningitis/parasitología , Estrongiloidiasis/etiología , Sobreinfección/parasitología , Infecciones por Escherichia coli/complicaciones , Humanos , Huésped Inmunocomprometido/inmunología , Linfoma de Células B Grandes Difuso/inmunología , Linfoma no Hodgkin/inmunología , Masculino , Persona de Mediana EdadRESUMEN
The efficacy and toxicity of a combination of etoposide (100 mg/m2 i.v. on days 1 to 3), Adriamycin (20 mg/m2 i.v. on days 1 and 8) and cisplatinum (40 mg/m2 i.v. on days 2 and 8) repeated every 4 weeks as an outpatient regimen were assessed in 29 consecutive patients with metastatic gastric cancer with measurable disease. Five of these patients were refractory to 5-Fluorouracil, Adriamycin, and Mitomycin C. Three of these previously treated patients responded to the etoposide. Adriamycin, cisplatinum (VAP) therapy. An overall objective response rate of 72.5% was achieved, including 14% that were complete responses. The median duration of response was 6.0 months; median overall survival was 7.2 months, overall one-year survival was 34.4%. Hematologic toxicity was intense, particularly among patients with lower performance status. Three patients died as a consequence of nadir sepsis episodes.